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Parkinson’s disease (PD) is the most common neurodegenerative movement disorder and
is characterized by the selective loss of dopaminergic neurons and the presence of Lewy
bodies. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent
cause of both familial and sporadic PD. One critical question is how PD-associated LRRK2
mutations cause neurodegeneration. Here, we discuss recent ﬁndings related to LRRK2-
mediated regulation of gene expression and translation and provide a critical assessment
of the current models that are used to address the impact of LRRK2 on the transcriptome.
A better understanding of these mechanisms could provide important new clues into the
function of LRRK2 during both normal and pathological conditions.
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INTRODUCTION
Parkinson’s disease (PD) is the most common movement disor-
der and the second most common neurodegenerative disease after
Alzheimer’s disease (Nussbaum and Ellis, 2003). It is estimated
that more than ﬁve million people worldwide suffer from PD and
related parkinsonisms. In affected individuals, motor dysfunction
is caused by selective dopaminergic neuronal loss in the substantia
nigra. Pathologically, PD is characterized by the presence of intra-
neuronal inclusions, namely Lewy bodies, which are composed
mainly of alpha-synuclein protein (Spillantini et al., 1997).
Mutations in leucine-rich repeat kinase 2 (LRRK2) represent a
substantial genetic component of both sporadic and familial PD
(Funayama et al., 2002; Paisan-Ruiz et al., 2004). LRRK2 (also
known as dardarin) is a large (approximately 280 kDa) multido-
main protein harboring a central catalytic tri-domainwithGTPase
and kinase activities (Cookson and Bandmann, 2010). It has been
shown that most, but not all, PD-associated LRRK2 mutations
display increased kinase activity, which is believed to contribute
to neurotoxicity (West et al., 2005; Greggio et al., 2006). Despite
these advances, the underlying molecular mechanisms involved in
LRRK2-mediated neurodegeneration remain poorly deﬁned.
Accumulating evidence supports the hypothesis that abnor-
mal regulation of gene expression and protein translation may
contribute to PD development. It is well known that the duplica-
tion or triplication of the alpha-synuclein gene, which increases
alpha-synuclein protein levels, can cause genetic PD (Chartier-
Harlin et al., 2004; Farrer et al., 2004). Furthermore, high levels
of insoluble alpha-synuclein protein in both familial and sporadic
PD may be explained, at least in part, by abnormal translation
of alpha-synuclein messenger RNA (mRNA). In the last 2 years,
several studies have implicated LRRK2 as a potentially important
player in transcriptional and translational control. Experiments in
various cell and animal models have demonstrated that LRRK2
modulation is associated with signiﬁcant changes in mRNA out-
put. Moreover, LRRK2 can bind to and phosphorylate several key
factors involved in posttranscriptional and translation control.
However, a crucial question in the ﬁeld is whether LRRK2 directly
modulates these processes. Here, we discuss these ﬁndings and
place them in a biological and pathological context. In addition,
we provide a critical assessment of the conceptual and analytical
issues presented by several studies. We hope these insights may
help our colleagues to move the ﬁeld forward and address these
important fundamental questions about LRRK2 biology.
LRRK2 AND ITS EFFECTS ON THE TRANSCRIPTOME
It is well established that changes in gene expression networks
occur during aging and that misregulation of these pathways can
have serious biological consequences. Understanding the effects of
LRRK2 on gene expression is of particular interest due to its role
in both normal and pathological aging processes.
One of the ﬁrst studies to assess the impact of LRRK2 deﬁciency
on the transcriptome was performed by Häbig et al. (2008) using
microarrays (Affymetrix U133 Plus 2.0) of human SH-SY5Y cells,
a dopaminergic neuroblastoma cell line, which had been treated
with small interferingRNAs (siRNAs) against LRRK2. The authors
obtained approximately a 75% reduction in endogenous LRRK2
expression in siRNA-treated cells compared to control cells. They
identiﬁed 187 mRNA transcripts that were signiﬁcantly misregu-
lated in the LRRK2-knockdown cells using 1.5-fold and P ≤ 0.05
(unadjusted) cut-off values. Of these transcripts, approximately
half were upregulated and half were downregulated, and a subset
of total genes (14 out of 16) was validated by quantitative RT-PCR
(qRT-PCR). Using the ingenuity pathway analysis (IPA) software,
this study identiﬁed CDC42, a protein involved in axonal guidance
www.frontiersin.org February 2012 | Volume 3 | Article 12 | 1
Dorval and Hébert LRRK2 in transcription and translation regulation
signaling, in ﬁve out of thenine canonicalmolecular pathways gen-
erated. Other differentially expressed transcripts encoded proteins
involved in biological processes such as the cell cycle and dif-
ferentiation, the actin cytoskeleton, nervous system development,
calcium signaling, and many others.
In a similar study,Devine et al. (2011) performed global mRNA
microarray analyses (Illumina) using two cellularmodels: LRRK2-
inducible HEK293 cells (wild-type and R1441C) and ﬁbroblasts
isolated from LRRK2 mutation (G2019S and Y1699C) carriers or
healthy non-mutant controls. Upon LRRK2 induction in HEK
cells, the exogenous levels of the wild-type LRRK2 protein or the
LRRK2 R1441C mutant protein increased by approximately 1.5-
and 2.5-fold, respectively, above the endogenous LRRK2 levels.
In both cell lines and in all experimental conditions tested, the
authors did not identify any signiﬁcant changes in mRNA tran-
script levels when 1.5-fold cut-off values and P values≤ 0.05 (after
correction for multiple testing) were applied. As no independent
validation was provided in this study, it remains unclear whether
high-ranking (e.g., P ≤ 0.05, without correction for multiple test-
ing) and/or lowly expressed genes (e.g., ≤1.5-fold) were indeed
misregulated in these models, and no further functional assays
were performed in this study.
Using embryonic stem (ES) cell-derived neurons, Schulz
et al. (2011) analyzed gene expression patterns via microarray
(GeneChip Mouse Genome 430 v2.0) during the neuronal dif-
ferentiation of wild-type and haploinsufﬁcient LRRK2+/− cells.
Interestingly, only 23 mRNA transcripts were signiﬁcantly misreg-
ulated in undifferentiated LRRK2+/− ES cells when compared to
controls after 1.5-fold cut-off values andP values≤ 0.01 (adjusted)
were applied. On the other hand, almost 3000 genes were affected
inLRRK2+/−differentiatedneuronsusing similar cut-off criteria.
The majority (approximately 80%) was downregulated, and some
showed greater than 20-fold differences. Several neurotransmitter
receptors as well as neurotransmitter release (GABA and gluta-
mate) were increased in the LRRK2+/− cultures, suggesting that
LRRK2 not only actively participates in neuronal differentiation
but also accelerates this process. Interestingly, other misregulated
genes included alpha-synuclein and the eukaryotic translation ini-
tiation factor 4E binding protein 1 (4E-BP1). By western blot, the
authors validated that three genes,Nanog, 4E-BP1, as well as ezrin,
radixin, andmoesin (ERM),were speciﬁcally downregulated in the
LRRK2+/− neurons.
Very recently, Nikonova et al. (2012) performed global mRNA
proﬁling experiments in LRRK2 knockout (KO) mice as well as
in PD-associated LRRK2 G2019S transgenic (Tg) mice. In the Tg
model, mutant LRRK2 is driven from the neuronal-speciﬁc pro-
moter CMVE–PDGF-β and is expressed three- to four-fold over
endogenous LRRK2. Using microarrays (Affymetrix GeneChip),
the authors identiﬁed approximately 600 mRNA transcripts that
were signiﬁcantly misregulated (P ≤ 0.01, adjusted) in some tis-
sues, including the cortex and striatum. In these assays, the authors
compared three biological replicates (n = 2 per genotype, thus
12 animals in total) per group (LRRK2 KO vs. WT). For the
LRRK2 G2019S mice, they used six biological replicates (n = 1
per genotype, thus 12 animals in total) per group (G2019S Tg
vs. non-Tg). Interestingly, a signiﬁcant portion of mRNA tran-
scripts showed opposite patterns of fold changes in KO vs. Tg mice
(after background correction using WT/non-Tg mice), suggesting
that increased LRRK2 kinase activity associated with the most fre-
quent LRRK2 G2019S mutation causes a gain of function with
regard to gene expression regulation. Biological pathway analysis
demonstrated that LRRK2 was signiﬁcantly enriched for mRNA
processing and ribosomal/translation functions. It is noteworthy
that the overall false discovery rates used in this study varied sig-
niﬁcantly between the different mouse models and tissues tested
and, in some cases, were above 80%. Thus, although a subset of
genes (between 5 and 30%, depending on the model) was vali-
dated by qRT-PCR, the physiological relevance of these ﬁndings
requires further evaluation. Also, the effects of LRRK2 WT over-
expression remain to be established. Finally, the age of the mice
used in this study was not provided, which makes it difﬁcult to
place these results within the context of aging. Nevertheless, this
was the ﬁrst study linking LRRK2 modulation and function with
gene expression misregulation in vivo in mammals.
To our knowledge, only two groups have analyzed gene expres-
sion proﬁles in post-mortem brain tissues of patients with LRRK2
mutations. Häbig et al. (2008) compared mRNA transcript levels
between idiopathic PD (IPD) patients (n = 5) and LRRK2 muta-
tion (G2019S) carriers (n = 5). In these assays, RNA was extracted
from the occipital cortex, where LRRK2 is expressed but where
little or no pathology (e.g., Lewy bodies or cell loss) was detected.
As in the previously mentioned cell lines (see above), the authors
observed no major changes in gene expression patterns between
LRRK2 carriers and either neurologically normal controls or IPD
patients. In an independent study, Botta-Orﬁla et al. (2012) per-
formed microarrays (Affymetrix GeneChip Human Exon 1.0 ST)
using RNA extracted from the putamen. In this study, the authors
compared groups of IPD (n = 5) and LRRK2 mutation (G2019S)
carriers (n = 3) to neurologically healthy controls (n = 5) and a
single asymptomatic G2019S-carrier. A total of 2874 genes were
signiﬁcantly altered (P ≤ 0.05, unadjusted) in the IPD group when
compared to controls, whereas only 38 genes were misregulated in
the LRRK2 G2019S group. However, only 227 and 5 genes in the
IPD and LRRK2 G2019S groups, respectively, were signiﬁcantly
altered after applying a twofold change cut-off. Within the IPD
group, 8 out of 10 genes were validated by qRT-PCR. Altered gene
expression related to biological processes involved diverse cell sig-
naling cascades and synaptic plasticity for both the sporadic PD
cases as well as the asymptomatic LRRK2 mutation carrier. How-
ever, no gene ontology categories were reported in the LRRK2
mutant group, even after lower thresholds were used in the analy-
ses. Unfortunately, the RNA integrity number (RIN) values or
other biochemical assessments of RNA quality were not included
in these studies. This is an important issue, asmost tissues had high
(>24 h) post-mortem intervals. Thus, the clinical and physiologi-
cal relevance of these results remain uncertain, and larger cohorts,
who will increase the statistical power of these ﬁndings, as well as
better tissue quality, are needed to draw deﬁnitive conclusions.
LRRK2 AND PROTEIN TRANSLATION REGULATION: FOCUS
ON 4E-BP1 AND THE eIF4 COMPLEX
The misregulation of translation can lead to misfolding and an
accumulation of aggregation-prone proteins, which are common
features of many age-related diseases including PD (Hindle, 2010).
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Protein translation is a highly energetic process, and its stimula-
tion can perturb cellular energy homeostasis. Below, we focus on
LRRK2-mediated regulation of protein synthesis and particularly
on the formation of the eIF4 translation initiation complex.
In Drosophila, it has been shown that LRRK2 interacts geneti-
cally with the TOR/4E-BP1 pathway (Imai et al., 2008), which is
involved in cell growth via protein synthesis (Wang and Proud,
2006). At the post-synapse, LRRK2 binds to and phosphorylates
4E-BP1, a binding inhibitor of the eukaryotic translation initiation
factor 4E (eIF4E; Figure 1). The phosphorylation and consequent
release of 4E-BP1 enables eIF4E to engage in protein translation
(Imai et al., 2008). Notably, pathogenic LRRK2 mutations can fur-
ther deregulate protein synthesis through hyperphosphorylation
of 4E-BP1, which can cause an age-dependent loss of dopamin-
ergic neurons (Imai et al., 2008). However, whether LRRK2 PD-
associated mutations that do not display increased kinase activity
have similar effects on 4E-BP1 and eIF4E function remains to
be determined. In another study, Pons et al. (2012) showed that
LRRK2 downregulation using siRNAs in various cancer cell lines
caused a signiﬁcant decrease in 4E-BP1 protein (but not mRNA)
levels, which is consistent with the results of previous studies
(Schulz et al., 2011). They further found that decreased LRRK2
(and 4E-BP1) expression was associated with increased cellular
proliferation. Thus, LRRK2 seems equally required for the regula-
tion of 4E-BP1 phosphorylation and protein stability, potentially
in a regulatory feedback loop.
Previous studies have shown that mutations in eIF4E are
involved in carcinogenesis and that mutant eIF4E is overexpressed
in various tumors (Wendel et al., 2007), which likely allows for the
translation of oncogenes and promotes cancer progression. Inter-
estingly,Chartier-Harlin et al. (2011) recently identiﬁedmutations
in eIF4G1, a binding partner of eIF4E and an essential component
of the eIF4F translation initiation complex (composed of eIF4A,
eIF4E, and eIF4G), in families with genetic PD. Two speciﬁc muta-
tions impaired the formation of the complex, and functional
analyses demonstrated a disruption in the binding of the eIF4G1
mutant A1205H to eIF3E as well as a defect in the binding of the
eIF4G1 A502V mutant to eIF4E. These mutants were also asso-
ciated with impaired mitochondrial dysfunction in response to
oxidative stress. This study proposes the exciting new viewpoint
that mutations in eIF4G1, and perhaps other components of the
protein synthesis machinery, are directly implicated in abnormal
mRNA translation in PD pathogenesis.
LRRK2 AND NON-CODING RNAs: A LINK BETWEEN
TRANSCRIPTION AND TRANSLATION
As mentioned above, LRRK2 harbors several protein–protein
interaction domains that are potentially involved in the scaffold-
ing of protein complexes and the binding of substrates (Li et al.,
2011). To date, two independent studies have demonstrated an
interaction between LRRK2 and the microRNA (miRNA) path-
way. These small (approximately 21–23 nucleotides) non-protein-
coding RNAs are essential for brain development and neuronal
survival and control precise neuronal functions (Hebert and De
Strooper, 2009; Bagetta et al., 2010). While the exact mode of
action of miRNAs remains under scrutiny, it has been shown
that they function to promote either the inhibition of transla-
tion or mRNA degradation (Huntzinger and Izaurralde, 2011). In
one study, Dachsel et al. (2007) used HEK293 cells overexpressing
wild-type human LRRK2 and co-immunoprecipitation followed
bymass spectrometry to identify 14 proteins that interacted specif-
ically with exogenous LRRK2, including eukaryotic translation
initiation factor 2C 1 (eIF2c1/Ago1) and eukaryotic translation
initiation factor 2C 2 (eIF2c2/Ago2). While not discussed in this
FIGURE 1 | Hypothetical model of LRRK2-mediated regulation of
protein translation. (A)Wild-type LRRK2 binds to and phosphorylates the
eiF4E inhibitor 4E-BP1. Free eiF4E interacts with other initiation complex
factors (eiF4A and eiF4G) to bind to the mRNA cap structure and initiate
protein translation. (B) PD-associated LRRK2 mutants with increased
kinase activity cause 4E-BP1 hyperphosphorylation, which over-stimulates
protein synthesis. The upregulation of protein translation can lead to
various consequences, such as protein aggregation, cell stress, and
ultimately, cell death. Note that binding of LRRK2 to 4E-BP1 is not
depicted here.
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study, argonaute (Ago) proteins are essential components of the
miRNA machinery (Peters and Meister, 2007). In a second study,
Gehrke et al. (2010) validated the interaction between LRRK2 and
Ago by co-immunoprecipitation in transfected HEK293 cells as
well as in brain extracts of transgenic Drosophila. By immunoﬂu-
orescence, the authors further showed that ectopic LRRK2partially
co-localized with Ago1 in dopaminergic neurons in vivo. Notably,
4E-BP1 also interacted with Ago1 in an age-dependent manner.
Moreover, the LRRK2 PD-associated mutant G2019S, which dis-
played increased kinase activity, stimulated this interaction, sug-
gesting a greater afﬁnity betweenAgo and phosphorylated 4E-BP1
(Figure 2). The authors identiﬁed two downstream effector miR-
NAs (let-7 and miR-184∗) as well as target genes (DP1 and E2F1)
involved in LRRK2-mediated neurodegeneration. Interestingly,
earlier studies have shown that the central domain of Ago proteins
exhibits sequence similarities to that of eIF4E and that human
Ago2 can compete with eIF4E to bind the cap structure of mRNAs
(Kiriakidou et al., 2007; Eulalio et al., 2008). Finally, it has been
reported thatAgo2 can be phosphorylated by unidentiﬁed kinases,
which reduces its binding afﬁnity for small RNAs (Rudel et al.,
2011). Taken together, these results highlight a potential cross talk
between LRRK2, the miRNA pathway, and eukaryotic transcrip-
tion factors for the modulation of protein synthesis and neuronal
survival. Clearly, these concepts need to be validated experimen-
tally aswell as investigatedusing other biologicalmodels, including
the mammalian brain.
Another interesting study provided a link between LRRK2 and
transcriptional control via non-coding RNAs. Indeed, Liu et al.
(2011) recently demonstrated that in mice, LRRK2 binds the
potent negative transcriptional regulatorNFAT,which functions in
immune responses. LRRK2 can also interactwith theNFAT repres-
sor complex that includes the large (800–3700 nucleotides) non-
coding RNA NRON. Knockdown or overexpression of NRON
abrogated or increased, respectively, the binding of exogenous
LRRK2 with the NFAT complex. Without affecting NFAT phos-
phorylation, LRRK2 sequestered the NFAT complex in the cytosol
and, as expected, prevented its functional translocation into the
nucleus. As most experiments were conducted in peripheral cells
or tissues, it would be interesting to study this pathway in the
brain using LRRK2 animal models. Whether NFAT and/or NRON
mutations are found in familial or sporadic PD patients remains
to be investigated.
CONCLUSION
Over the past 20 years, many advances have been made regard-
ing the identiﬁcation of genes and pathways associated with PD.
However, the exact contribution and interaction between these
genes for the etiology of the disease remain unclear. In this review,
we discussed recent ﬁndings related to the inﬂuence of LRRK2 in
the regulation of gene transcription and protein translation, two
ubiquitous and fundamental biological processes. The current lit-
erature provides ample evidence that LRRK2 participates actively
in translation initiation through the phosphorylation of 4E-BP1
and likely other factors as well. Furthermore, both LRRK2 and
4E-BP1 interact with core components of the miRNA pathway
to potentially act as a “molecular hub” for gene expression and
protein synthesis. Mutations in genes related to protein synthe-
sis in genetic PD highlight the signiﬁcance of protein translation
dysfunction in this disease.
To date, most researchers have relied on microarrays to assess
the effects of LRRK2 on the genome. As discussed herein, the
choice of platform, the number of replicates, the power of the
statistical test, and the cut-off criteria can considerably impact
the overall conclusions, especially when the effects are subtle.
These factors, combined with the high false-negative and false-
positive rates associated with microarrays in general, necessitate
the independent validation of selected genes to make deﬁnitive
conclusions. We believe that it is safe to conclude that LRRK2
does inﬂuence mRNA levels. However, whether these effects are
direct and whether they reﬂect a global or speciﬁc loss (or gain) of
function remains open to debate. As of now, the consequences of
LRRK2 modulation on protein output remain largely unexplored,
such that additional studies are required to fully appreciate its role
in the cell. Obviously, the choice of biological model, ranging from
FIGURE 2 | Hypothetical model of LRRK2-mediated regulation of the
miRNA pathway. (A)Wild-type LRRK2 binds to and phosphorylates
4E-BP1. Phosphorylated 4E-BP1 then binds to eiF2c/Ago, which can
potentially modulate miRNA binding to its mRNA targets and affect gene
expression. Interestingly, eiF2c/Ago can also compete with free eiF4E to
bind the mRNA cap structure, possibly affecting protein translation in
addition to gene transcription via miRNAs. Note that the interaction
between LRRK2 and eiF2c/Ago is not shown here. (B) PD-associated
LRRK2 mutants could affect the miRNA pathway by increasing miRNA
stability and function, potentially through the increase in the afﬁnity
between Ago and phospho-4E-BP1. Obviously, various changes in
translation and/or transcription regulation are conceivable in this model
and need to be investigated further. Misregulation of these pathways
could have important biological consequences.
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cells to humans, adds to the complexity of these analyses. Simi-
larly, the selection of LRRK2 mutations may also have an impact
on the experimental outcome. As noted previously, not all PD-
associated LRRK2 mutants (e.g., R1441C/G/H) display increased
kinase activity. In these speciﬁc cases, it is thought that the GTPase
domain contributes to LRRK2-mediated toxicity (Xiong et al.,
2010),possibly independently of binding toGTP/GDPnucleotides
(Taymans et al., 2011). Moreover, the function (or dysfunction)
of LRRK2 may be cell and/or tissue-speciﬁc. In agreement with
this hypothesis, Tong et al. (2010) showed that genetic deletion
through germ-line transmission of targeted LRRK2 in mice had
no measurable effect on dopaminergic neurons, whereas it was
highly toxic to the kidneys. Finally, it remains possible that LRRK2
may function mainly under stress conditions. Undoubtedly, the
results discussed herein provide a strong foundation for further
validation and functional studies with regard to the role of LRRK2
in the regulation of transcription and translation as well as in the
pathogenesis of PD.
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